Introduction: The anti-fibrinolytic, tranexamic acid (TA) can be proposed as a long term prophylaxis for hereditary angioedema (HAE), and seems to be specifically efficient for HAE with plasminogen gene mutation (HAE-PLG), a subset of HAE with normal C1-INH (HAE-nC1-INH). Here, PLG is linked to hereditary angioedema.